An interventional study of The objective fitting method of the EAS based on the thresholds of electrocochleography is the intervention of our study. and The subjective adjustment of an EAS based on thresholds from the pure tone audiogram. in Fitting Methods by EAS Patients, sponsored by Luzerner Kantonsspital. Not yet recruiting. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-24.
Sponsored by Luzerner Kantonsspital · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of this clinical study is to investigate how the fitting of an EAS (electrical acoustic stimulation) based on electrocochleography (ECochG) thresholds compares to fitting based on pure tone audiogram thresholds in terms of speech intelligibility in quiet and noise. The personal feedback from the study participants regarding the question of better fitting and the resulting sound quality should also be included in the analysis.
As the indications for Cochlear Implant (CI) Surgery expand to also include hearing impaired patients with some residual hearing in the ipsilateral (to be implanted) ear, residual hearing preservation during the surgical intervention becomes even more important. It is also known from the literature that patients will benefit from having good residual acoustic hearing after CI-Implantation in terms of the sound quality. This is particularly so for speech comprehension in noise as well as for music perception with the CI.
Present-day clinical Sound Processor programming software provides Electric Acoustic Stimulation (EAS) to account for preserved residual hearing. For an optimized EAS fitting, it is postulated here that optimal conditions are achieved when the electric and acoustic stimulation do not overlap. To achieve this, the acoustic stimulation ought to be limited to only regions where there is still useful acoustic hearing, while the electric stimulation should also be restricted to regions where there is no longer significant useful acoustic hearing. In the Maestro clinical software, the threshold for significant useful acoustic hearing is set to 65 dB Hearing Level (HL). This then determines the cut-off frequency between the acoustic and electric stimulation regions.
The standard clinical Maestro software computes this cut-off based on a regular pure tone audiogram (PTA) which has been manually stored in the software. However, it is arguable that this does not always represent an accurate cut-off frequency required for optimal fitting because the audiogram thresholds themselves are subjective in nature and can often vary in a test-retest situation, depending on the attention and reaction times of the patient. It has been reported that the unaided thresholds do not play a significant role in the EAS fitting. In this respect, it may be more accurate and beneficial to use objective measures such as electrocochleography (ECochG) to determine the thresholds of the residual hearing.
The current family of Med-El Cochlear Implants are equipped with the capability to perform ECochG measurements using the implant's own intracochlear electrodes within the scala tympani. The measurements can also be conducted intraoperatively or postoperatively. This intracochlear ECochG feature of the implants therefore allows us to objectively determine the residual hearing thresholds.
The aim of this study is to discuss the advantages of objective fitting of the EAS compared to subjective fitting using a PTA with respect to speech intelligibility in quiet and in noise. The personal feedback from the study participants regarding the question of better fitting and the resulting sound quality should also be included in the analysis.
From the existing literature, it is not expected that there should be any significant gender effects. This also does not belong to the primary aims of this study and we will not be investigating this aspect.
Luzerner Kantonsspital is the lead sponsor of 61 studies on the registry; 22 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In this sequence, the EAS is fitted in the first three months (period 1) using the subjective fitting method based on the thresholds in the pure tone audiogram. This is followed by three months (period 2) fitting using the objective fitting method based on the thresholds from electrocochleography.
Other: The objective fitting method of the EAS based on the thresholds of electrocochleography is the intervention of our study. · Other: The subjective adjustment of an EAS based on thresholds from the pure tone audiogram.
In this sequence, the EAS is fitted in the first three months (period 1) using the objective fitting method based on the thresholds from electrocochleography. This is followed by three months (period 2) fitting using the subjective fitting method based on the thresholds in the pure tone audiogram.
Other: The objective fitting method of the EAS based on the thresholds of electrocochleography is the intervention of our study. · Other: The subjective adjustment of an EAS based on thresholds from the pure tone audiogram.
Measured ECochG thresholds will be used in the initial EAS fitting in period 1 for sequence B. For sequence A, the ECochG-based EAS fitting (with up-to-date ECochG thresholds) will take place three months later at the beginning of period 2.
The control intervention is the subjective EAS fitting based on PTAs. This is provided to sequence A at the beginning of period 1 baseline and to sequence B at the beginning of period 2.
Speech Recognition Threshold (SRT50)
The primary outcome measure is the Speech Recognition Threshold (SRT50) at three months after EAS fitting (either objective or subjective EAS fitting in a cross-over design). The SRT50 measures speech understanding in noise and is defined as the Signal-to-Noise Ratio (measured in dB SNR) which yields 50% speech understanding, as determined by the OLSA test.
Time frame: Three months after EAS fitting
Subjective level of auditory benefit
A secondary outcome measure is subjective level of auditory benefit at three months after EAS fitting (either objective or subjective EAS fitting in a cross-over design), as determined using the HISQUI-19 (Hearing Implant Sound Quality Index) questionnaire.
Time frame: Three months after EAS fitting
Subjectively preferred EAS fitting method
The subjectively preferred EAS fitting method at the end of the study will be examined.
Time frame: at the end of the study, six months after baseline
Post-operative ECochG and PTA tresholds
Post-operative ECochG and PTA thresholds at three months after EAS fitting (either objective or subjective EAS fitting in a cross-over design).
Time frame: Three months after EAS fitting (either objective or subjective EAS fitting)
No study locations are listed for this record.
Plan to share: No
Start is estimated for May 2026; primary completion for Nov 2027, 18 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Luzerner Kantonsspital